News

Adults with cystic fibrosis (CF) make as much use of most routine preventive healthcare services as adults in the general population, and in some cases more than they do, according to a recent analysis of U.S. insurance claims data. This services — of growing importance as CFTR modulator…

Staying physically active, especially engaging in more vigorous exercise regularly, is important for lung health and life quality in adolescents and adults with cystic fibrosis (CF), a study reports. Better lung function and exercise capacity were key factors in a patient’s overall quality of life, the researchers found, adding…

The Cystic Fibrosis Foundation has announced new funding of up to $15 million to Prime Medicine to further develop its gene-editing technology — called Prime Editing — for cystic fibrosis (CF). The award is part of the foundation’s $500 million Path to a Cure initiative, which aims…

The first volunteer has been dosed in a Phase 1 clinical trial evaluating SION-109, an experimental oral treatment for cystic fibrosis (CF), as announced by Sionna Therapeutics, the therapy’s developer. After receiving the green light from the U.S. Food and Drug Administration, the trial has enrolled healthy volunteers to…

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease status to 4D-710, an inhaled gene therapy for people with cystic fibrosis (CF). The designation means 4D Molecular Therapeutics (4DMT) would be eligible to receive a priority review voucher from the FDA if its gene therapy…

The nasal microbiome — the community of microorganisms that live in the nose — obtained through nasal lavage correlates with inflammation in the nose and sinuses of children with cystic fibrosis (CF),  a study indicates. The effect wasn’t observed when samples were obtained by a nasal…

No significant link was seen between an increase in body mass index (BMI), a measure of body fat based on weight and height, and higher blood fats and vitamin levels in people with cystic fibrosis (CF) being treated with Trikafta (elexacaftor/tezacaftor/ivacaftor), a study in adult and pediatric patients…

Discontinuing dornase alfa while on Trikafta (elexacaftor/tezacaftor/ivacaftor) could cut down on prescription costs by more than $1 billion each year in the U.S., according to estimates based on data from a randomized controlled trial. The savings would not compromise health, at least not for the short term, as people…

The diversity and relative abundance of microbes in the lungs — or the lung microbiome — was generally stable over an eight-month period in people with cystic fibrosis (CF), regardless of whether they had experienced a pulmonary exacerbation, according to a recent study. In the short term, using…

Two imaging techniques, called elastography and spectroscopy, can detect liver stiffness (hardness) and the buildup of fat in the liver in children with cystic fibrosis (CF) — particularly among those with CF-related liver disease — a study found. Importantly, because elastography and spectroscopy are noninvasive, these scans may offer…